Summary by Moomoo AI
CORNING JERRY BIOPHARMACEUTICALS (ALPHAMAB ONCOLOGY) ANNOUNCED THE LATEST RESULTS OF A PHASE I CLINICAL TRIAL OF ITS DRUG JSKN003 FOR THE TREATMENT OF HER2-EXPRESSED LATE-STAGE SOLID TUMORS ON APRIL 5-10, 2024. The study showed that JSKN003 had good tolerability and safety in patients with late-stage and metastatic solid tumors, and showed initial antitumor activity. The results include data from 32 patients, most of whom received at least three-line systemic therapy. In terms of efficacy, the objective mitigation rate (ORR) and disease control rate (DCR) are 56.3% and 90.6%, respectively. The drug has a low rate of hematotoxicity and interstitial lung disease (ILD). JSKN003 IS AN ANTIBODY DUPLICATED DRUG (ADC) TARGETING HER2 CURRENTLY IN CLINICAL TRIALS IN AUSTRALIA AND CHINA, AND ADVANCING A PHASE III CLINICAL TRIAL IN CHINA. Corning Jerry Biopharmaceuticals is a biopharmaceutical company focused on the treatment of tumors with several products in different stages of development.